ANNEE 2013

Publié le 06/02/2014 à 14h45 (mis à jour le 02/09/2015 à 10h38)

PHARMACOLOGIE FONDAMENTALE

Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, Houssier M, Roussel B, Besse-Patin A, Combes M, Mir L, Monbrun L, Bezaire V, Prunet-Marcassus B, Waget A, Vila I, Caspar-Bauguil S, Louche K, Marques MA, Mairal A, Renoud ML, Galitzky J, Holm C, Mouisel E, Thalamas C, Viguerie N, Sulpice T, Burcelin R, Arner P, Langin D. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol, 2013, 11, 2, e1001485.

Mias C, Coatrieux C, Denis C, Genet G, Seguelas MH, Laplace N, Rouzaud-Laborde C, Calise D, Parini A, Cussac D, Pathak A, Sénard JM, Galès C. Cardiac fibroblasts regulate sympathetic nerve sprouting and neurocardiac synapse stability. Plos One 2013, 8,(11):e79068.

PHARMACOLOGIE CLINIQUE

Cornu C, Binquet C, Thalamas C, Vigouroux C, Gaillard S, Ginhoux T, Vaz B, Jossan C, Felin A, Sailly A, Gueyffier F, Journot V, Kassai B. Public clinical trials : which kind of monitoring should be used ? Therapie 2013, 68, 135-41.

Moulis G, Gaudin C, Cassaing S, Tournier E, Balardy L. Nodules cutanés révélant une alternariose systémique. Press Med 2013, 42, 1421-23.

Denuelle M, Fabre N. Functional neuroimaging of migraine. Rev Neurol 2013, 169, 380-9.

Schapira AHV, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate – to extended-release pramipexole in advanced Parkinson’s disease. Europ J of Neurol 2013, 20, 180-87.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol, O, Marek K. Pramipexole in patients with early Parkinson’s disease (PROUD) : a randomized delayed-start trial. Lancet Neurol 2013, 12, 747-755.

Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Halbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel-Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltete D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Kruger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-brittinger C, Deuschl G ; EARLYSTIM Study group (Czernecki V, Pineau F, Negovanska V, Welter ML, Corvol JC, Cornu P, Moller B, Nebel A, Witt K, Raethjen J, Meister IG, Kuhn J, Donner K, Kessler J, Kuhn A, Muller B, Faust K, Chabardes S, Pollak P, Fraix V, Rascol O, Arbus C, Danet L, Groiss SJ, Elben S, Hartmann C, Sudmeyer M, Ledily S, Sauvaget A, Trenkwalder C, Richter-Dreske W, Wachter T, Weiss D, Eusebio A, Azulay JP, Polo G, Pinto S, Levin J, Dornier S, Pene F, Hourton D, Quintin M, Hoffart-Jourdain C, Brocvuelle H, Partowinia-Peters M, Balthasar K, Stein M, Harnisch S, Reuss A, Aminossadati B, Nasemann C, Stoker V, Diener HC, Lehmacher W, Keravel Y, Roosen K, Deuschl G, Agid Y, Schade-Brittinger C, Reub A, Burchardi N, Houeto JL, Krack P. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013, 368, 610-622.

Rascol O. Extended-release carbidopa-levodopa in Parkinson’s disease. Lancet Neurol 2013, 12, 325-326.

Hauser RA, Hsu A, Espay AJ, Sethi K, Stacy M, Ondo W, O’Connell M, Gupta S. Extended-release carbidopa-levodopa compared with immediate-release carbidopa-levodopa in patients with Parkinson’s Disease and motor fluctuations : a phase 3 randomised, double-blind trial. Lancet Neurol 2013, 12, 346-356.

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, Del Sorbo F, Tolosa E, Cardoso A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner W, Tison F, Poewe W on behalf of EMSA-SG. The natural history of multiple system atrophy : a prospective european cohort study. Lancet Neurology 2013, 12, 264-274.

Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Dis 2013, 28, 86-95.

Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Song GE. Which dyskinesia scale best detects treatment response ? Mov Disord 2013, 28, 341-346.

Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schupbach M, Tolosa E, Trenkwalder C, Schapira A, Bererdelli A, Oertel WH. Summary of the recommandations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 2013, 20, 5-15.

Peran P, Nemmi F, Méligne D, Cardebat D, Peppe A, Rascol O, Caltagirone C, Demonet JF, Sabatini U. Effect of levodopa on both verbal and motor representations of action in Parkinson’s Disease : A fMRI study. Brain Lang 2013, 125, 324-329.

Perez-Lloret S, Rey MV, Ratti PL, Rascol O. Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundam and Clinical Pharmacol 2013, 27, 81-95.

Perez-Lloret S, Rey MV, Ratti PL, Pavy Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin. Emerging Drugs 2013, 18, 39-53.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with L-dopa-induced dyskinesia : 13-week randomized, controlled, dose-finding study. Mov Disord 2013, 28, 1838-46.

Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira A, Emre M, Nissinen H, Leinonen M, Stocchi F. For the Stalevo Reduction in dyskunesia evaluation in Parkinson’s disease (STRIDE-PD) investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013, 28, 1064-71.

Tison F, Nègre-pagès L, Meissner WG, Dupouy S, Li Q, Thiolat ML, Thiollier T, Galitzky M, Ory-Magne F, Milhet A, Marquine L, Spampinato U, Rascol O, Bezard E. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism and related Disorders 2013, 19, 416-421.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013, 20, 50-56.

Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson’s disease : the PROUD study. Mov Disord, 2013, 25, 1627-32.

Rascol O. Jejunal levodopa infusion in Parkinson’s disease. Lancet Neurol. 2013, pii : S1474-4422(13)70291-6. doi :
10.1016/S1474-4422(13)70291-6.

Perez-Lloret S. Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson’s disease : an old drug revisited. Eur J of Neurol 2013, 20, 1427-8.

Meissner WG, Foubert-Samier A, Dupouy S, Debs R, Gerdelat-Mas A, Cochen de Cok V, Schrag A, Rascol O, Tison F, Pavy-Le Traon A. Validation of the french version of the MSA health-related quality of life scale (MSA-QoL). Rev Neurol 2013, 169, 53-58.

Perez-Lloret S, Videla AJ, Richaudeau A, Vigo D, Rossi M, Cardinali DP, Perez-Chada D. A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance : an exploratory cross-sectional study in teenagers. J Clin Sleep Med. 2013, 15, 469-73.

Rascol O. Physical exercise in Parkinson disease : moving toward more robust evidence ? Mov Disord 2013, 28, 1173-75.

Klebe S, Golmard JL, Nalls MA, Saad M, Subgleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbaumer G, Charfi R, Klein C ; Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC ; French Parkinson’s disease genetics study group : international Parkinson’s disease genomics consortium (IPDGC). The val158MetCOMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 2013, 84, 666-73.

Ferreira JJ, Neutel D, Mestre TA, Galitzky M, Thalamas C, Santos AT, Sampaio C, Rascol O. Usefulness of OSLER test in Parkinson’s disease. Mov Disord 2013, 14, 297-300.

Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, De Bie RMA, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Ostergaard K, Poewe W, Pollak P, Van der Linden C, Oertel W. Selecting deep brain stimulation on infusion therapies in advanced Parkinson’s disease : an evidence-based review. J Neurol 2013, 260, 2701-14.

Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord 2013, 19, 548-552.

Labrunée M, Despas F, Marque P, Guiraud T, Galinier M, Sénard JM. Pathak A. Acute electromyostimulation decresases muscle sympathetic nerve activity in patients with advanced chronic heart failure (EMSICA study). Plos One 2013, Nov 12, 8(11):e7943.

Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GYH, Verheugt FWA, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013, 34, 1708-13

Guiraud T, Labrunée M, Gaucher K, Despas F, Meyer P, Bosquet L, Vaccaro A, Bousquet M, Galinier M, Sénard JM, Pathak A. High-intensity interval exercise improves vagal tone and decreases arrhythmias in patients with chronic heart failure. Med Sci Sport 2013, 45, 1861-7.

Pathak A, Lebrin M, Vaccaro A, Sénard JM, Despas F. Pharmacology of levosimendan : inotropic, vasodilatory and cardioprotective effects. Journal of Clinical Pharmacy and Therapeutics 2013, 38, 341-349.

Hanon O, Lee YS, Pathak A. Association between eprosartan-based hypertension therapy and improvement in cognitive function score : long-term follow-up from the OSCAR observational study. JRAAS 2013, 1-8.

Lantelme P, Courand PY, Pathak A. Renal denervation : a plea for wisdom. Arch of Cardiovasc Dis 2013, 106, 121-3.

Dumonteil N, Vaccaro A, Despas F, Labrunée M, Marcheix B, Lambert E, Esler M, Carrie D. Transcatheter aortic valve implantation (TAVI) reduces sympathetic activity and normalizes arterial spontaneous baroreflex in patients with aortic stenosis. JACC Cardiovasc interv 2013, 6, 1195-1202.

Franchitto N, Despas F, Labrunée M, Galinier M, Sénard JM, Sénard JM, Pathak A. Cardiorenal anaemia syndrome in chronic heart failure contributes to increased sympathetic nerve activity. Int J Cardiol 2013, 168, 2352-57.

Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr ; GREAT Network. Association between elevated blood glucose and outcome in acute heart failure : results from an international observational cohort. J Am Coll Cardiol. 2013, 26 ;61, 820-9.

Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A ; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure : the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013, 168, 2186-94

Lambert E, d’Udekem Y, Cheung M, Ika Sari C, Inman J, Ahimastos A, Eikelis N, Pathak A, King I, Grigg L, Schlaich M, Lambert G. Sympatetic and vascular dysfunction in adult patients with fontan circulation. Int J of Card 2013, 167, 1333-38.

Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X. Management of arterial hypertension in adults : 2013 guidelines of the french society of arterial hypertension. Press Med 2013, 42, 819-25.

Pathak A. Variabilité tensionnelle et rigidité artérielle. Les cahiers de l’artère 2013, 6, 6-7.

Satge J, Gremeaux V, Guiraud T, Granger R, Pathak A, Labrunée M. Comment optimiser l’alliance thérapeutique autour de l’activité physique dans les maladies cardiovasculaires ? Lett Méd Phys et Réadapt 2013, 29, 119-28.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia : an adjusted comparison of mortality and morbidity. Haematologica 2013, 98, 197-8.

Moulis G, Sommet A, Lapeyre-Mestre M. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : comment on the article by Sinard et al. Arthritis and Rheumatism 2013, 65, 1670-74.

Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin A. Long-term consequences of acute pain for patients under Methadone of buprenorphine maintenance treatment. Pain Physician 2013, 16, 739-747.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Mintzes B, Lexchin J, Wilkes MS, Beaulieu MD, Reynolds E, Sutherland J, Durrieu G. Pharmaceutical sales representatives and patient safety. J Gen Med Intern 2013 ; 28, 1395.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical sales representatives and patient safety : a comparative prospective study of information quality in Canada, France and the United States. J Gen Med Intern 2013 ; 28, 1368-75.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk on anti-TNF-a at recommended doses in adult rheumatoid arthritis : a meta-analysis with intention to treat and per protocol analyses. Plos One 2013, DOI : 10.1371.

Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDS : a case/non case analysis of spontaneous reports from the french pharmacovigilance database 2002-2006. Fundam and Clinical Pharmacol 2013, 27, 223-230.

Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML, Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel C, Castot A, Kreft-Jaus C, Pérault-Pochat MC. The PREGVAXGRIP study : a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)V2009 influenza. Drug saf 2013, 36, 455-65.

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen) : The Multinational Case-Population SALT Study. Drug Saf. 2013, 36, 135-44.

Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation : Results from the Study of Acute Liver Transplant (SALT). Drug Saf 2013, 36, 757-64.

Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013, 69, 1819-26.

Olivier-Abbal P, Teisseyre AC, Montastruc JL. Comparison of serious adverse reactions between thalidomide and lenalidomide : analysis in the French pharmacovigilance database. Med Oncol 2013, 30, 733.

Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions : a pharmacovigilance study in France. Eur J Clin Pharmacol 2013, 69,885-888.

Fuzier R, Serres I, Guitton E, Lapeyre-Mestre M, Montastruc JL ; French Network of Pharmacovigilance Centres. Adverse drug reactions to gabapentin and pregabalin : a review of the French pharmacovigilance database. Drug Saf. 2013, 36, 55-62.

Montastruc F, Schmitt L, Montastruc JL, Pathak A. QT interval and antidepressant use : a cross sectional study of electronic health records. BMJ 2013 ;346:f288 doi : 10.1136/bmj.f288

Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer : which lessons can be drawn ? Drug Saf 2013, 36, 693-707.

Amar J, Lieber A, Montastruc F, Bagheri H, Pathak A, Montastruc JL. Arterial hypertension and resistance ton antihypertensive treatment : a new adverse drug reaction with Modafinil. Therapie 2013, 68, 53-4.

Bezzina C, Bondon-Guitton E, Montastruc JL. Inhaled corticosteroid-induced hair depigmentation in a child. J Drugs Dermatol. 2013, 1, 119-20.

Abadie D, Durrieu G, Roussin G, Montastruc JL. Effets indésirables "graves" du tramadol : bilan 2010-2011 de pharmacovigilance en France. Thérapie 2013, 68, 77-84.

Durrieu G, Mazau B, Jégu J, Lapeyre-Mestre M, Delord JP, Montastruc JL. Drugs and cancer : an analysis of the french pharmacoviiglance database. Thérapie 2013, 68, 149-54.

Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Senard JM, Pathak A. Effets indésirables cardiaques des chimiothérapies. Press Med 2013, 42, 26-39.

Damase-Michel C, Hurault-Delarue C. Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern. Evid Based Med doi:10.1136/eb-2013-101495

Dupouy J, Moulis G, Tubery M, Ecoiffier M, Sommet A, Poutrain JC, Arlet P, Lapeyre-Mestre M. Which adverse events are related to health care during hospitalization in elderly lnpatients ? Int J Med Sci 2013, 9, 1224-30.

Sommet A, Georgel B, Poutrain JC, Oustric S, Bourrel R, Montastruc JL, Birebent J. Différence de taux de substitution des médicaments génériques en Midi-Pyrénées en fonction des classes pharmaco-thérapeutiques. Revue d’Epidémiologie et de Santé Publique 2013, 61, 539-44.

Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Casto-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourashemi F, Charmes JP. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France : a national multicentre cross-sectional study. Pharmacoepidemiol and Drug Saf 2013, 22, 952-60.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. The nursing home effect : a case study of residents with potential dementia and emergency departments visits. J Am Dir Assoc 2013, 14, 901-5.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. Prevalence and associations of the use of proton-pump inhibitors in nursing homes : a cross-sectional study. JAMDA 2013, 14, 265-9.

Michaud M, Gaudin C, Brechemier D, Moulis G, Astudillo L, Lavialle-Guillotreau V, Balardy L. Un syndrome de Reynolds révélant un thymome malin. Rev Med Inter 2013, 34, 171-3.

Gallini A, Gardette V, Vellas B, Lapeyre-Mestre M, Andrieu S, Brefel-Courbon C. Persistent use of analgesic medications in mild-to-moderate Alzheumer’s disease. Drugs Aging 2013, 30, 439-45.

Montastruc F, Laffont M, Bagheri H, Montastruc JL. Potentially inappropriate medications in the elderly in France : a study in community pharmacies in 2011-2012. Eur J Clin Pharmacol 2013, 69, 741-2.

De Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rollland Y. Potential underuse of analgesics for recognized pain in nursing home residents with dementia : a cross-sectional study. Pain 2013, 2427-31.

Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, Montastruc JL, Andrieu S. Potentially inappropriate medication use among patients with Alzheimer disease in the REALFR cohort : be aware of atropinic and benzodiazepine drugs ! Eur J Clin Pharmacol 2013, 69, 1589-97.

Roussin A, Bouyssi A, Pouché L, Pourcel L, Lapeyre-Mestre M. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults : a cross-sectional investigation in France. Plos One 2013, DOI : 10.1371.

Peyrière H, Eiden C, Micallef J, Lapeyre-Mestre M, Faillie JL, Blayac JP. Slow-release oral morphine sulfate abuse : results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Eur Addict Res 2013, 19, 235-244.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. Indicators of benzodiazepine use in nursing home residents in France : a cross-sectional study. JAMDA 2013, 14, 29-33.

Dupouy J, Dassieu L, Bourrel R, Poutrain JC, Bismuth S, Oustric S, Lapeyre-Mestre M. Effectiveness of drug tests in outpatients starting opioid substitution therapy. Journal of Substance abuse treatment 2013, 44, 515-521.

Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, Mallaret M, Jouanjus E, Micallef J. Doctor shopping reveals geographical variations in opioid abuse. Pain Physicial 2013, 16, 89-100.

Dupouy J, Bez J, Barsony J, Oustric S, Lapeyre-Mestre M. Cycles de traitement par médicament de substitution aux opiacés dans une cohorte de patients suivis 5 ans en médecine ambulatoire.Thérapie 2013, 68,155-161.

Lapeyre-Mestre M.  Addiction médicamenteuse : quelles données pour évaluer et prévenir ? Cairn.infoPyschotropes 2013, 19, 65-80.

Orriols L, Foubert-Samier A, Gadegbeku B, Delorme B, Tricotel A, Philip P, Moore N, Lagarde E, CESIR Research Group. Prescription of antiepileptics and the risk of road traffic crash. J Clin Pharmacol 2013, 53, 339-44.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. A questionnaire to document self-medication history in adult patients visqiting emergency departments. Pharmacoepidemiology and Drug Saf 2013, 22, 151-9.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Adoue D. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. Eur J Hematol 2013, 90, 438-9.

Le Lay M, Fournier JP, Montastruc JL. Interactions médicamenteuses potentielles en médecine générale : comparaison de deux études transversales en 1997 et 2012. Thérapie 2013, 68, 411-3.

Lapeyre-Mestre M, Sapède C, Moore N et les participants à la table ronde n° 5 de Giens XXVIII : Bidault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Pharmacoepidemiology studies : what levels of evidence and how can they be reached ? Thérapie 2013, 68, 247-52.

Despas F, Rocher H, Laurent G. Anticancer drug adherence. Bull cancer 2013, 100, 473-484.

Moulis G, Sailler L, Pugnet G, Astudillo L, Arlet P. Biologics in relapsing polychondritis : a case series. Clin and Experimental Rheum 2013, 31, 937-9.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. A multicentric individually-tailored controlled trial of education and professional support to nursing home staff : research protocol and baseline data of the IQUARE study. J Nutr Health Aging. 2013, 17, 173-8.

Moulis G, Pugnet G, Sailler L, Astudillo L, Arlet P. Abatacept in relapsing polychondritis. Ann Rheum Dis 2013 ;72:e27 doi:10.1136/annrheumdis-2013-204336.

Montastruc JL, Laffon de Mazières C, Montastruc F, Moulis G. Réflexions éthiques après l’affaire du Médiator°. Bioethique.com/index. 27 novembre 2013.

Montastruc JL, Montastruc F. Prescribe, but also know how to "deprescribe". Prescrire Int 2013, 22, 192.

Montastruc F, Moulis G, Gardette V, Durrieu G, Montastruc JL. Junior doctors attitudes towards drug companies. Prescrire Int 2013, 22, 195.

Fuzier R, Fabre B. Aiguilles échogènes : intérêt et performance ? Le Praticien en anesthésie Réanimation 2013, 17, 266-269.

Bourlier V, Saint-Laurent C, Louche K, Badin PM, Thalamas C, de Glisezinski I, Langin D, Sengenes C, Moro C. Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training. J Clin Endocrinol Metab 2013, 9, 3739-47.

Chollet F, Acket B, Raposo N, Albucher JF, Loubinoux I, Pariente J. Use of antidepressant medications to improve outcomes after stroke : Use of antidepressant medications to improve outcomes after stroke. Curr Neurol Neurosci Rep 2013, 13, 318.

Abadie D. Médicaments, peau et soleil. Bulletin d’information de pharmacologie. Septembre 2013.

Lacroix I. Médicaments de substitution des dépendances aux opiacés/données épidémiologiques. Chapitre du "guide concernant l’usage de substances psychoactives". Edition Respadd 2013.

Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourashemi F. Proinflammatory cytokines, aging, and age-related diseases. JAMDA 2013, 1-6.

Montastruc F, Moulis G, Gardette V, Durrieu G, Montastruc JL. Attitudes des internes en médecine vis-à-vis de l’industrie pharmaceutique. Prescrire 2013 355, 387.

Montastruc JL. Actualités sur les antiagrégants. Avril 2013.

Montastruc JL. Attention aux interactions NACOs et amiodarone. Bulletin d’information de pharmacologie. Septembre 2013.

Montastruc JL. Benzodiazépines et démences. Avril 2013.

Montastruc JL. Effets indésirables systémiques et oro-pharyngés des corticostéroïdes inhalés. Bulletin d’information de pharmacologie. Septembre 2013.

Montastruc JL. Ne pas confondre : hypolipémiants et hypolipémiants ! Bulletin d’information de pharmacologie. Septembre 2013.

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Is the risk of tumor necrosis factor inhibitor-induced lupus the same with monoclonal antibodies and soluble receptor ? A case/non case study in a nationwide pharmacovigilance database. Arthritis Rheum 2013, 65, 612-3.

Pathak A. Les génériques : l’avis du pharmacologue. Repères en gériatrie 2013, 15, 30-32.